GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PHIO
Phio Pharma is a biotech company developing RNA interference therapy for oncology. Its stock price represents a venture bet on its technology platform. The stock price reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Dna
Phio Pharmaceuticals is a biotech company using self-delivering RNA interference (RNAi) technology to activate the immune system against cancer. We've classified it as a "DNA" company, and the chart below shows how the market is assessing the prospects for this breakthrough in immuno-oncology.
Broad Market Index - GURU.Markets
Phio Pharmaceuticals is a biotech company developing RNA interference therapy to enhance anti-tumor immunity. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Phio compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
PHIO - Daily change in the company's share price PHIO
Phio Pharmaceuticals Corp.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its RNA therapy in oncology.
Daily change in the price of a set of shares in a market segment - Dna
Phio Pharmaceuticals uses cutting-edge RNA interference technology, placing it in the volatile biotech sector. The chart below shows the average daily price swings for this industry. It serves as a benchmark for assessing whether PHIO shares are riskier or less risky than their sector peers.
Daily change in the price of a broad market stock, index - GURU.Markets
Phio Pharmaceuticals is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PHIO
Phio Pharmaceuticals Corp.'s year-over-year performance is a story about the development of RNA interference therapy for oncology. Its 12-month market cap depends entirely on clinical trial data, where it must prove that its drugs can effectively "switch off" the genes responsible for tumor growth, its key scientific bet.
Annual dynamics of market capitalization of the market segment - Dna
As an early-stage biotech, Phio is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its RNA therapy. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Phio Pharmaceuticals, with its RNA interference platform, is at the forefront of gene therapy. Its performance relative to the market is a clear bet on a breakthrough technology. Investors are buying not profits, but the hope of a revolution in immuno-oncology, which creates a highly volatile price action.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PHIO
Phio Pharmaceuticals is a biotech company developing RNA interference therapy. Being an early-stage company, its monthly valuation is based on the potential of its platform. News of progress in preclinical studies are the main drivers.
Monthly dynamics of market capitalization of the market segment - Dna
Phio Pharmaceuticals is a biotech company developing immunotherapeutic drugs based on self-delivered RNA interference (INTASYL) technology for the treatment of cancer. The graph below shows the dynamics of the biotech sector, where RNA technologies are one of the most advanced areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Phio Pharmaceuticals is developing immunotherapy based on RNA interference technology. This is cutting-edge science. The company's shares are driven by news of clinical trials and partnerships, and their performance is completely disconnected from overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PHIO
Phio Pharmaceuticals is developing RNA interference therapy for oncology. Its weekly stock price is a speculative bet on the success of this cutting-edge technology, with clinical data being the main driver.
Weekly dynamics of market capitalization of the market segment - Dna
Phio Pharmaceuticals operates in the field of RNA interference, the cutting edge of genetic medicine. The chart shows how this innovative company's stock performs compared to the DNA and RNA therapeutics sector. Is its volatility a price for breakthrough technologies or a common feature of the entire niche?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Phio Pharmaceuticals is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
PHIO - Market capitalization of the company PHIO
The Phio Pharmaceuticals chart shows how the market values an RNA interference platform for immuno-oncology. Its market cap reflects investors' belief that the company's technology can "switch on" and "switch off" genes to enhance the immune system's attack on cancer cells.
PHIO - Share of the company's market capitalization PHIO within the market segment - Dna
Phio Pharmaceuticals is a biotech company developing immuno-oncology drugs based on self-delivering RNA interference (RNAi) technology. In the cutting-edge DNA/RNA medicine segment, its market capitalization reflects the potential of this platform. The company's size reflects its bet that its technology will effectively "disable" genes that promote tumor growth.
Market capitalization of the market segment - Dna
Phio Pharmaceuticals is using RNA interference for immunotherapy. How big is this revolutionary arena? The chart below shows the pulse of the DNA technology sector. Its extreme volatility reflects both the enormous potential for "reprogramming" immune cells and the high risks of this cutting-edge science.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Phio Pharmaceuticals chart shows how the market values RNA interference technology in immuno-oncology. The company's market cap is a venture bet on its platform of "self-delivering" RNAs that can "switch on" cancer-fighting genes. This diagram illustrates how science is attempting to reprogram the immune system.
Book value capitalization of the company, segment and market as a whole
PHIO - Book value capitalization of the company PHIO
For Phio Pharmaceuticals, which is developing RNA interference therapy, book value is its tangible foundation, consisting of rights to the INTASYL platform and financial reserves for preclinical and clinical trials. The chart below shows how this scientific and financial capital has changed.
PHIO - Share of the company's book capitalization PHIO within the market segment - Dna
Phio Pharmaceuticals Corp. is an RNA therapeutics company. Its tangible assets are the laboratories where its platform for silencing cancer-causing genes is being developed. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Dna
Phio Pharmaceuticals is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Phio focuses on developing RNA-based drugs, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Phio Pharma's assets are not drugs, but rather a patented self-delivering RNA interference technology (INTASYL), which "turns off" genes that promote cancer development. The book value reflects the laboratory facilities and capital for developing this innovative platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PHIO
Phio Pharmaceuticals is developing RNA interference therapy for oncology. Its value lies in its self-delivering RNA platform. The chart shows how the market is pricing this cutting-edge, yet risky, scientific approach.
Market to book capitalization ratio in a market segment - Dna
Phio Pharmaceuticals develops immunostimulatory drugs based on RNA interference for cancer treatment. This is cutting-edge technology. The chart shows that the company's market value is based on expectations for its scientific platform, not on its current tangible assets.
Market to book capitalization ratio for the market as a whole
Phio Pharmaceuticals uses RNA interference technology in oncology. The company's entire value lies in its patents and the potential of this scientific approach. This chart demonstrates how valuations in cutting-edge biotech fields depend on investors' faith in science rather than current financial performance or assets.
Debts of the company, segment and market as a whole
PHIO - Company debts PHIO
Phio Pharmaceuticals is a biotech company developing RNA interference therapy for oncology. This is a cutting-edge scientific platform that requires significant, long-term investment in research. This chart shows how the company is raising capital to fund its innovative, yet early-stage, developments.
Market segment debts - Dna
Phio Pharmaceuticals is a clinical-stage biotech company developing RNA interference-based immunotherapy. This cutting-edge technology requires significant investment in R&D. This chart shows its financial position and its complete reliance on equity capital to fund its unique research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PHIO
Phio Pharmaceuticals works in the field of RNA interference. This chart shows the financial structure of an early-stage biotech company. For a company focused on fundamental science, debt is an extreme risk. Its survival depends entirely on shareholders' faith in the technology and their willingness to finance the long journey to eventual success.
Market segment debt to market segment book capitalization - Dna
Phio Pharmaceuticals is a pioneer in RNA interference, a technology that can "switch off" disease-causing genes. This is a cutting-edge scientific field. The chart shows the overall debt burden in the biotech sector, which helps understand how Phio finances its fundamental, but highly capital-intensive and long-term research.
Debt to book value of all companies in the market
Phio Pharmaceuticals is a biotech company developing RNA interference therapy for oncology. It is a cutting-edge scientific platform. This chart, reflecting the debt of an established economy, emphasizes that Phio's funding is entirely dependent on investors' faith in the potential of its technology, rather than traditional loans that require stable revenue.
P/E of the company, segment and market as a whole
P/E - PHIO
For Phio Pharmaceuticals, a company developing RNA therapeutics, the P/E ratio is not meaningful. It doesn't have stable profits. Its valuation on this chart is arbitrary. The company's value reflects investors' faith in its scientific platform and its potential to create a new class of drugs.
P/E of the market segment - Dna
Phio Pharmaceuticals is a clinical-stage biotech developing RNA interference (RNAi)-based immune-boosting drugs for cancer treatment. This chart shows the average valuation for the sector, helping to understand how the market views this cutting-edge scientific platform.
P/E of the market as a whole
Phio Pharmaceuticals is a biotech company developing RNA interference-based immunotherapy. Its valuation is a pure bet on its scientific platform. It is not tied to the general economic cycles depicted by this chart. Phio's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PHIO
Phio Pharmaceuticals is a biotech company developing immune-boosting drugs based on self-delivering RNA interference (RNAi) for the treatment of cancer. This chart reflects investor expectations for its innovative platform. The valuation is based on the technology's potential to make tumors more vulnerable to the immune system.
%20P%2FE%20PHIO&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PHIO&v=1772532836301 "Chart of the company's future (projected) P/E PHIO")
Future (projected) P/E of the market segment - Dna
Phio Pharmaceuticals is a biotech company developing RNA interference-based immunotherapy for cancer treatment. Its valuation relative to other oncology biotechs reflects investor sentiment on its innovative platform, betting that its technology can "turn on" the immune system to fight tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772532836337 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Phio Pharmaceuticals develops RNA interference-based drugs for use in immuno-oncology. The company's technology aims to "turn on" the immune response against tumors. This chart shows the overall risk appetite. For cutting-edge biotech companies like Phio, market optimism is critical to funding lengthy and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772532836355 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PHIO
Phio Pharmaceuticals is a biotech company developing immunotherapeutic drugs based on self-delivered RNA interference technology. The financial indicators shown in the chart represent investments in this cutting-edge platform for silencing cancer-promoting genes.
Profit of companies in the market segment - Dna
Phio Pharmaceuticals is developing RNA interference-based immunotherapeutics for cancer treatment. This chart reflects the financial status of the DNA/RNA therapeutics sector. It shows how close this cutting-edge research field is to creating commercially viable products or whether it is still in the fundamental research stage.
Overall market profit
Phio Pharmaceuticals develops immunotherapeutic drugs based on RNA interference, a cutting-edge technology in oncology. The company's value, like that of other early-stage biotechs, is determined by the potential of its scientific platform. Macroeconomic cycles, as seen in this chart, are of little significance for PHIO.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PHIO
Phio Pharmaceuticals develops RNA interference-based immunotherapeutics for cancer treatment. The company's future profitability depends on the success of its innovative platform. This chart shows how analysts assess the potential of this cutting-edge technology for creating a new class of anticancer drugs.
%20profit%20of%20the%20company%20PHIO&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PHIO&v=1772532836601 "Graph of future (projected) profit of the company PHIO")
Future (predicted) profit of companies in the market segment - Dna
Phio Pharmaceuticals is a pioneer in the development of self-delivering RNA interference (RNAi) compounds for immuno-oncology. Their technology aims to "reprogram" cells directly within the tumor. This graph shows forecasts for the DNA therapy segment, illustrating the enormous hopes placed on gene technologies for the creation of a new generation of cancer drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772532836661 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
For Phio Pharmaceuticals, which operates in the cutting-edge field of RNA interference, this schedule is important for the availability of venture capital. Expectations of economic growth are increasing the influx of funds into risky but promising biotech platforms. A downturn, however, is forcing investors to be more conservative.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772532836722 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PHIO
Phio Pharmaceuticals is developing an immunostimulatory therapy based on RNA interference. This figure, in the absence of revenue, represents a pure bet on its technology. Investors evaluate scientific potential, not current cash flows.
P/S market segment - Dna
Phio Pharmaceuticals is a biotech company developing immune-boosting drugs based on self-delivering RNA interference (RNAi) technology for the treatment of cancer. This chart shows the average valuation in the DNA technologies sector. It reflects investor confidence in the potential of Phio's innovative platform to improve immunotherapy.
P/S of the market as a whole
Phio Pharmaceuticals Corp. is a biotech company developing immunostimulatory drugs based on RNA interference for the treatment of cancer. This cutting-edge technology aims to "turn on" the immune system. The company's valuation is based on the potential of this platform. This chart shows the market premium for breakthrough scientific approaches.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PHIO
Phio Pharmaceuticals is developing RNA interference therapy for immuno-oncology. The company's valuation is based on the future potential of its platform for "reprogramming" immune cells. The chart demonstrates investors' belief that this technology will lead to the development of effective cancer treatments.
%20P%2FS%20PHIO&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PHIO&v=1772532837264 "The graph of the company's future (projected) P/S PHIO")
Future (projected) P/S of the market segment - Dna
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based drugs for immuno-oncology. Its technology silences genes that prevent the immune system from attacking cancer cells. This chart shows how investors view the potential of this cutting-edge platform.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772532837394 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the gene therapy market. For Phio Pharmaceuticals, a company developing RNA interference therapy for oncology, this reflects faith in cutting-edge technologies. Market optimism helps fund approaches that can "switch off" genes that promote cancer cell growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772532837396 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PHIO
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based immunomodulatory drugs for cancer treatment. This chart reflects revenue from partnerships. Future revenue will depend on the success of clinical trials of its drugs, which "switch off" genes that suppress the immune response to tumors.
Sales of companies in the market segment - Dna
Phio Pharmaceuticals is a biotech company developing immunotherapeutic drugs based on self-delivering RNA interference technology. This chart illustrates the growth of the gene therapy sector. Phio's platform enables the "silencing" of genes that suppress the immune response, a new and promising approach to cancer treatment.
Overall market sales
Phio Pharmaceuticals Corp. develops RNA interference-based drugs for immuno-oncology. The company's growth depends on investment in its technology platform. The overall economic situation, shown in this chart, influences investors' risk appetite and their willingness to invest in cutting-edge research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PHIO
Phio Pharmaceuticals is a biotech company developing immunotherapeutic drugs based on RNA interference (RNAi) technology for the treatment of cancer. This approach allows for the "silencing" of genes that promote tumor growth. This graph reflects analysts' expectations for the success of clinical trials of this innovative oncology platform.
%20sales%20of%20the%20company%20PHIO&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PHIO&v=1772532837576 "Schedule of future (projected) sales of the company PHIO")
Future (projected) sales of companies in the market segment - Dna
Phio Pharmaceuticals is a biotech company developing immunotherapeutic drugs based on RNA interference. This chart shows expectations for the DNA technology sector. It reflects interest in genetic approaches for turning genes on and off to treat diseases, particularly cancer.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772532837584 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Phio Pharmaceuticals Corp. is a biotechnology company developing immunotherapeutics based on self-delivered RNA interference technology. Its valuation depends on the success of its scientific platform. The overall economic situation, reflected in this chart, influences the investment climate in the biotechnology sector, which is important for funding advanced R&D platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772532837680 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PHIO
Phio Pharmaceuticals is developing an RNA interference-based immunostimulatory therapy for cancer treatment. This chart shows the financial picture at the clinical trial stage. Negative values represent investments in a cutting-edge scientific platform designed to "turn on" the immune system to fight tumors.
Market segment marginality - Dna
Phio Pharmaceuticals is developing RNA interference-based drugs for immuno-oncology. For a research-stage biotech company, this graph serves as a potential indicator. It shows the average profitability in the sector that Phio aims to achieve if their innovative approach proves effective and is commercialized.
Market marginality as a whole
Phio Pharmaceuticals is a biotechnology company developing immunotherapeutic drugs based on RNA interference. This total market profitability graph does not reflect its research activities. Its potential lies in the development of a new class of drugs. Success depends on the results of preclinical and clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company PHIO
Phio Pharmaceuticals is a biotechnology company using self-delivering RNA interference (RNAi) technology to develop immuno-oncology drugs. This chart shows a small scientific team focused on preclinical and early clinical trials.
Share of the company's employees PHIO within the market segment - Dna
Phio Pharmaceuticals is a pioneer in the field of RNA interference, developing drugs that "switch off" disease-causing genes. This chart shows the percentage of leading biologists and RNA technology specialists the company attracts. It reflects its concentration of unique scientific talent at the forefront of gene therapy.
Number of employees in the market segment - Dna
Phio Pharmaceuticals develops drugs using RNA interference technology that "switch off" genes responsible for tumor growth. This graph shows how fundamental discoveries in genetics are becoming the basis for the creation of new drugs and entire companies that attract top molecular biologists to work on therapies of the future.
Number of employees in the market as a whole
Phio Pharmaceuticals uses RNA interference, a cutting-edge technology in gene therapy. This graph shows the current state of the labor market, but companies like Phio are working ten steps ahead. They are creating demand for specialists in entirely new fields of genetics and bioinformatics, creating professions that don't yet exist on a mass scale.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PHIO (PHIO)
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi) therapies for oncology. This chart represents the net intellectual capital valuation. The company's value is based on its unique delivery platform (INTASYL). The chart shows how highly the market values this scientific potential per scientist working on it.
%20of%20the%20company%20PHIO%20(PHIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PHIO-PHIO&v=1772532838292 "Chart of market capitalization per employee (in thousands of dollars) of the company PHIO (PHIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Phio Pharmaceuticals uses RNA interference to develop immuno-oncology drugs. This is a cutting-edge scientific field. The chart shows the enormous value the market can place on each scientist working on this breakthrough technology. This reflects investor expectations for the future of gene therapy.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772532838349 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Phio Pharmaceuticals Corp. is a biotechnology company developing immuno-oncology drugs based on RNA interference. This chart shows the average market value generated by one researcher, illustrating the high valuation of cutting-edge scientific platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772532838403 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PHIO (PHIO)
Phio Pharmaceuticals is a clinical-stage biotech company working with RNA interference technology. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to develop its platform.
%20Chart%20PHIO%20(PHIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PHIO-PHIO&v=1772532838473 "Company Profit Per Employee (in thousands of dollars) Chart PHIO (PHIO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Phio Pharmaceuticals is a biotech company developing RNA interference-based drugs for immuno-oncology. Its value lies in its unique scientific platform. At the clinical trial stage, this graph will likely show negative profit per employee, reflecting the high costs of maintaining a research team and the norm for innovative companies in this field.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772532838578 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Phio Pharmaceuticals (PHIO) is a clinical-stage biotech developing RNAi therapy (gene silencing) for immuno-oncology (treatment of skin cancer, glioblastoma). It is an R&D company. This chart shows the general market standard for profitability per employee. For PHIO (which is not yet profitable), this is a benchmark: if successful, their IP will generate high profitability per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772532838605 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PHIO (PHIO)
Phio Pharmaceuticals is a biotech company developing RNA interference-based immunotherapy. This chart shows the potential of its cutting-edge scientific platform. For a development-stage company, it is an indicator of the future revenue that could be generated if its approach is successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PHIO-PHIO&v=1772532838630 "Sales chart per company employee PHIO (PHIO)")
Sales per employee in the market segment - Dna
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi) therapies for immuno-oncology. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Phio's scientific team.
Sales per employee for the market as a whole
Phio Pharmaceuticals is a clinical-stage biotech company developing RNA interference (RNAi) therapies for immuno-oncology. The company has no commercial revenue, which is irrelevant. Its value lies in the potential of its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company PHIO (PHIO)
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi) for cancer immunotherapy. It's a speculative, early-stage technology. This chart shows the odds of failure. "Bears" believe their scientific approach won't prove effective in the clinic, and the company will burn through all of its investors' capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PHIO-PHIO&v=1772532838843 "Short Shares Chart for the Company PHIO (PHIO)")
Shares shorted by market segment - Dna
Phio Pharmaceuticals Corp. uses RNA interference (RNAi) technology to "disable" genes that prevent the immune system from attacking cancer. This is a form of immunotherapy. This chart reflects the total short position in the biotech sector (DNA/RNA therapeutics). High values indicate general investor skepticism about the success of clinical trials of these cutting-edge technologies.
Shares shorted by the overall market
Phio Pharmaceuticals uses RNA interference (RNAi) technology for cancer immunotherapy. This is cutting-edge but complex science. This chart reflects the general pessimism. When investors are fearful, they are unwilling to bet on fundamental R&D. They see PHIO as a cash-burning company and sell off shares, fearing share dilution or trial failure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PHIO (PHIO)
Phio Pharmaceuticals uses RNA interference (RNAi) technology to "turn off" genes that prevent the immune system from attacking cancer. It's a breakthrough, but early technology. This chart tracks the hype around their platform, showing "overheated" (above 70) on positive data or "oversold" (below 30) pending results.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PHIO-PHIO&v=1772532838984 "RSI 14 indicator chart for the company's stock PHIO (PHIO)")
RSI 14 Market Segment - Dna
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based drugs. Their self-delivering RNA technology aims to disable cancer-causing genes. This chart measures the collective excitement in the gene therapy sector. It helps determine whether the entire speculative segment is oversold.
RSI 14 for the overall market
For Phio Pharmaceuticals, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PHIO (PHIO)
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi) to enhance cancer immunotherapy. Their drugs "make" tumors visible to the immune system. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PHIO-PHIO&v=1772532839208 "A chart showing analyst consensus forecasts for the expected stock price. PHIO (PHIO)")
The difference between the consensus estimate and the actual stock price PHIO (PHIO)
Phio Pharmaceuticals is a biotech company that uses self-delivered RNA interference (RNAi) to disable genes responsible for cancer growth. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PHIO-PHIO&v=1772532839303 "A chart showing the difference between the consensus forecast and the actual stock price. PHIO (PHIO)")
Analyst consensus forecast for stock prices by market segment - Dna
Phio is an R&D biotech company developing RNA interference technology (INTASYL), which allows for the "silencing" of genes responsible for cancer growth. This chart reflects analysts' overall expectations for the DNA technology sector, demonstrating whether experts believe RNA therapy will be a breakthrough in oncology.
Analysts' consensus forecast for the overall market share price
Phio Pharmaceuticals is a biotech company developing RNA interference (RNAi)-based drugs that "switch off" genes that promote cancer growth. This chart reflects the overall market "risk appetite." For PHIO, a clinical-stage company with an innovative platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PHIO
Phio Pharma is an R&D company working in RNA interference (RNAi). Their signature feature is a self-delivering (sd-rxRNA) platform that allows them to silence genes that cause cancer (immuno-oncology) or fibrosis (scarring). This graph is a clear indicator of their faith in their R&D platform. It reflects their (very risky) progress in preclinical research.
AKIMA Market Segment Index - Dna
Phio Pharmaceuticals (PHIO) is a biotech company developing a self-delivering RNA interference therapy (INTASYL). Their technology disables cancer-promoting genes directly within the tumor. The chart shows the segment's average index, helping investors assess how this cutting-edge gene technology compares to the industry average.
The AKIM Index for the overall market
Phio Pharmaceuticals is a biotech company using the INTASYL (RNA interference) platform for immuno-oncology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early scientific story compares to overall economic trends and interest in RNA technologies.
